Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Slides:

Advertisements

Similar presentations

Neoplastic Fever Caused by Lung Cancer

Advertisements

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Jeffrey Bradley, MD Journal of Thoracic Oncology

A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Avoidance of completion pneumonectomy by sparing the right middle lobe

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report Kazutaka Fujita, MD, Yuko.

MET-Mutated NSCLC with Major Response to Crizotinib

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

The Moth-Eaten Lung Journal of Thoracic Oncology

Numb Chin Syndrome: An Ominous Sign of Lung Cancer

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma Kazuhisa Nakashima, MD, Tateaki Naito, MD, Shota Omori, MD, Shusuke Yoshikawa,

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK Satoshi Anai, MD, Masafumi.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Metastatic Angiosarcoma Arising From the Right Atrium: Unusual Presentation and Excellent Response to Treatment in a Young Patient Martin Fehr, MD, Max.

Neoplastic Fever Caused by Lung Cancer

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Aya Fukuizumi, MD Journal of Thoracic Oncology

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Identification of a subcentimeter pulmonary adenocarcinoma using intraoperative near- infrared imaging during video-assisted thoracoscopic surgery Jane.

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination

Drug Interaction Between Complementary Herbal Medicines and Gefitinib

Matthew Reichert, MD, Eric S. Bensadoun, MD

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Jeffrey Bradley, MD Journal of Thoracic Oncology

Multiple Pulmonary Nodules in an Elderly Woman

Nicholas W. Choong, MD, Robert S. Hellman, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Sean Connolly, MD, Peter Hountras, MD CHEST

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Metastatic Lung Cancer to the Pancreas

S-1 Treatment for Chemorefractory Thymic Carcinoma

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

Journal of Thoracic Oncology

David Garfield, MD Journal of Thoracic Oncology

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD, PhD, Manabu Ono, MD, Tokiwa Tamai, MD, PhD, Masakazu Ichinose, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 8, Pages e73-e74 (August 2013) DOI: 10.1097/JTO.0b013e318293dfc1 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 PET and CT of a 53-year-old woman. Both PET scan (A) and CT scan (B) showed a mass in the right lower lobe with bilateral, multiple pulmonary nodules. PET, positron emission tomography; CT, computed tomography. Journal of Thoracic Oncology 2013 8, e73-e74DOI: (10.1097/JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Crizotinib-induced interstitial lung disease. A, A chest CT scan performed 14 days after initiation of crizotinib treatment showing a decrease in size of the main tumor, but visible bilateral ground-glass opacities. B, CT scan 5 days after cessation of crizotinib and initiation of corticosteroid, showed improvement of air space consolidations, despite the right lower lobe tumor enlargement. CT, computed tomography. Journal of Thoracic Oncology 2013 8, e73-e74DOI: (10.1097/JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Chest computed tomography scan before and after crizotinib retreatment. A, Before treatment with crizotinib, the scan showed the right lower mass and bilateral lung metastases. B, Two months after the initiation of crizotinib, the scan showed a partial remission of the right lower lung tumor without recurrence of interstitial lung disease. Journal of Thoracic Oncology 2013 8, e73-e74DOI: (10.1097/JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions